Literature DB >> 23680197

Novel systemic drugs for psoriasis: mechanism of action for apremilast, a specific inhibitor of PDE4.

Peter H Schafer, Robert M Day.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23680197     DOI： 10.1016/j.jaad.2012.10.064

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN： 0190-9622            Impact factor:   11.527


× No keyword cloud information.
  4 in total

1.  A Nonhuman Primate PET Study: Measurement of Brain PDE4 Occupancy by Roflumilast Using (R)-[11C]Rolipram.

Authors:  Akihiro Takano; Tolga Uz; Jesus Garcia-Segovia; Max Tsai; Gezim Lahu; Nahid Amini; Ryuji Nakao; Zhisheng Jia; Christer Halldin
Journal:  Mol Imaging Biol       Date:  2018-08       Impact factor: 3.488

2.  Recurrence of Melanoma after Starting Apremilast for Psoriasis.

Authors:  Thomas G Salopek
Journal:  Case Rep Dermatol       Date:  2017-08-03

3.  Apremilast as an adjuvant therapy for calcinosis cutis.

Authors:  Sultan H Qiblawi; David P Fivenson
Journal:  JAAD Case Rep       Date:  2019-09-25

4.  Cyclic AMP Regulates Key Features of Macrophages via PKA: Recruitment, Reprogramming and Efferocytosis.

Authors:  Graziele L Negreiros-Lima; Kátia M Lima; Isabella Z Moreira; Bruna Lorrayne O Jardim; Juliana P Vago; Izabela Galvão; Lívia Cristina R Teixeira; Vanessa Pinho; Mauro M Teixeira; Michelle A Sugimoto; Lirlândia P Sousa
Journal:  Cells       Date:  2020-01-06       Impact factor: 6.600
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.